Selumetinib is a potent, non-ATP competitive, small molecule inhibitor of MEK which has demonstrated significant anti-tumour activity against colorectal cancer in vitro in cell line studies and in vivo, in mouse xenograft models20–22. Here, MAP2K7 is linked to neoplasm.